Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine

By LabMedica International staff writers
Posted on 20 Feb 2024

Currently, mammography is the standard method for breast cancer diagnosis, but it has several limitations. More...

The primary concern with mammograms is their lack of infallibility. False negatives can occur when normal breast tissue conceals cancer, and false positives may arise from anomalies that resemble cancer but are benign, causing unnecessary anxiety for patients. Additionally, the radiation involved in these tests could potentially contribute to the development of cancer over time. Now, a pain-free, low-cost, sensitive, radiation-free device that can detect breast cancer in urine with a sensitivity of 88.33% could bring about a shift in the diagnostic approach toward this disease.

The Blue Box Biomedical Solutions (Barcelona, Spain) has developed an affordable, user-friendly, and portable device that can detect breast cancer using a urine sample. This device, known as the Blue Box, employs an innovative eNose (electronic nose) to detect the smell of urine. It features a chemical sensor array that identifies breast cancer biomarkers present in urine that become volatile when heated, indicating the presence of the disease. The device also incorporates an AI algorithm that analyzes the sensor activation heatmap to determine if a subject has breast cancer, identifying patterns unique to the disease. This AI can detect breast cancer based on the presence and relative intensities of multiple volatile organic compounds (VOCs). Blue Box performs as similarly as possible to expensive and big lab machinery without the need for expensive and big lab machinery, complex sample handling procedures, and trained personnel.

The Blue Box offers a significant improvement in breast cancer treatment and diagnosis, benefiting both patients and healthcare professionals. Its problem-oriented design ensures accessibility, allowing for the early detection and treatment of more breast cancer cases. Its widespread use could transform breast cancer prevention by enabling earlier and simpler diagnoses, thus allowing for more timely treatments. Additionally, it eliminates the discomfort and anxiety associated with traditional testing methods. The company has successfully run two pilots to validate its technology in 7 hospitals, with over 450 patients. It now plans to launch the device in 2025 by bringing it to gynecology clinics with a Diagnostic-as-a-Service subscription model and a pay-per-test revenue stream that will be shared with doctors.

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.